Sales of multiple sclerosis drug Tecfidera helped treat this pharmaceutical firm to a hale 2014 (though recent results missed targets).
Looking for leads, investment insights, or competitive intelligence?Buy Now
Company Information
| Location | Cambridge, MA |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Fortune 500 Rank | 298 |
| Fortune 500 Profile | http://fortune.com/fortune500/biogen-298/ |
| Current Streak | 1 |
| Years on List | 1 |
| CEO | George A. Scangos |
| Website | http://www.biogen.com |
Revenue, Net Income
| Revenue Past Four Quarters | 10,129 |
| Net Income Past Four Quarters | 3,277 |
Growth Rates
| EPS 3 yr Annual Growth Rate | 35% |
| Rev 3 yr Annual Growth Rate | 26% |
| Total Return 3 yr Annual Rate | 41% |
| Beat S&P 3 yr Total Return? | yes |
Rank
| EPS Growth Rank | 69 |
| Revenue Growth Rank | 63 |
| Total Return Rank | 53 |
